Education
About Us
Working with TipRanks
Follow Us
Biofrontera (BFRI)
NASDAQ:BFRI
BFRI Stock Chart & Stats
$0.97
$0.09(8.11%)
At close: 4:00 PM EST
$0.97
$0.09(8.11%)
Day’s Range― - ―
52-Week Range$0.54 - $1.87
Previous CloseN/A
Volume12.39M
Average Volume (3M)101.58K
Market Cap
$10.99M
Enterprise Value$4.41M
Total Cash (Recent Filing)$3.42M
Total Debt (Recent Filing)$4.91M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Apr 03, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding10,668,442
10 Day Avg. Volume76,439
30 Day Avg. Volume101,578
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.36
Price to Sales (P/S)0.16
P/FCF Ratio-0.58
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue0.12
Enterprise Value/Gross Profit0.18
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$6.00Price Target Upside518.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset MonetizationThe transaction is positive for Biofrontera as it monetizes an asset that was not aligned with the company’s future focus, boosting the company’s cash position.
Market ExpansionXepi can be used in a younger patient population (2 months of age and older) compared to other options, which provides the product with another important competitive advantage.
Product ApprovalXepi is the only drug in its class approved by the FDA with activity against bacteria that are resistant to treatment with methicillin (MRSA).
Bears Say
Cost Of Goods SoldAnalyst is raising COGS estimates by 15%, assuming the EU tariff rate prevails.
Supply Chain DependencyBiofrontera Inc. currently sources Ameluz from Biofrontera Pharma GmbH in Germany, which in turn sources from a single unaffiliated contract manufacturer in Switzerland.
Tariff ImpactPotential tariff and pricing uncertainty on pharmaceuticals are lessened but not eliminated following an announcement from Pfizer, as Biofrontera Inc. appears to fall under the current 15% tariff regime negotiated with the European Union.
Biofrontera News
BFRI FAQ
What was Biofrontera’s price range in the past 12 months?
Biofrontera lowest stock price was $0.54 and its highest was $1.87 in the past 12 months.
What is Biofrontera’s market cap?
Biofrontera’s market cap is $10.99M.
When is Biofrontera’s upcoming earnings report date?
Biofrontera’s upcoming earnings report date is Apr 03, 2026 which is in 141 days.
How were Biofrontera’s earnings last quarter?
Biofrontera released its earnings results on Nov 13, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.58 by -$0.04.
Is Biofrontera overvalued?
According to Wall Street analysts Biofrontera’s price is currently Undervalued.
Does Biofrontera pay dividends?
Biofrontera does not currently pay dividends.
What is Biofrontera’s EPS estimate?
Biofrontera’s EPS estimate is 0.17.
How many shares outstanding does Biofrontera have?
Biofrontera has 10,668,442 shares outstanding.
What happened to Biofrontera’s price movement after its last earnings report?
Biofrontera reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.58. Following the earnings report the stock price went up 2.105%.
Which hedge fund is a major shareholder of Biofrontera?
Currently, no hedge funds are holding shares in BFRI
Company Description
Biofrontera
Biofrontera AG is a biopharmaceutical company focused on the development and commercialization of innovative products for the treatment of skin diseases, particularly skin cancer and other dermatological conditions. The company operates primarily in the dermatology sector, with a strong emphasis on photodynamic therapy and topical treatments. Biofrontera's core products include Ameluz, a prescription medication for the treatment of actinic keratosis, and the BF-RhodoLED, a light source used in conjunction with Ameluz for effective therapy.
BFRI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Biofrontera's earnings call reflects a successful first half of 2025 marked by record sales, strategic independence, and strong financial backing, despite increased net losses and legal costs. The overall sentiment is buoyed by positive operational changes and future growth prospects.View all BFRI earnings summariesBFRI Stock 12 Month Forecast
Average Price Target
$6.00
▲(518.56% Upside)
Technical Analysis
Ownership Overview
12.24% Insiders
0.46% Mutual Funds
18.49% Other Institutional Investors
68.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---